BioNexus Gene Lab (BGLC) Return on Sales (2018 - 2026)

BioNexus Gene Lab's Return on Sales history runs 9 years deep, the most recent figure standing at 0.24% for Q1 2026.

• In Q1 2026, Return on Sales fell 24.0% year-over-year to 0.24%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Sales came in at 0.24% for Q1 2026 at BioNexus Gene Lab, down from 0.02% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2023 to a low of 0.24% in Q1 2026.
• A 5-year average of 0.02% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales increased 1 bps in 2024 and declined 24 bps in 2026, its largest moves.
• BioNexus Gene Lab's Return on Sales stood at 0.0% in 2022, then jumped by 939 bps to 0.0% in 2023, then sank by 184 bps to 0.0% in 2024, then slumped by 1543 bps to 0.02% in 2025, then plunged by 1011 bps to 0.24% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.24%, 0.02%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison